



NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX PRESENTS RESULTS FROM BRITISH BLINDED PANEL OF SPIKED HUMAN BLOOD SAMPLES

TORONTO, ON, February 11, 2008 – Amorfix Life Sciences Ltd. presented today the decoded results of a blinded panel of spiked human blood samples, tested by Amorfix's EP-vCJD™ assay, at the 12th Annual Transmissible Spongiform Encephalopathies international conference. The samples had been provided by the British National Institute for Biological Standards and Control (NIBSC).

“The results show we have significantly improved our EP-vCJD™ assay which was 10 times more sensitive in this more-extensive blinded panel compared to the initial panel,” said Dr. George Adams, Chief Executive Officer, Amorfix. “In addition, we have now developed a potential confirmatory assay which is 20 times more sensitive again and may be able to verify any contaminated blood donation many years before the donor has symptoms of the disease.”

The British Government has confirmed, the screening test, EP-vCJD™, was able to detect with 100% accuracy spiked blood samples up to a 1:1,000,000 (1:100,000 of 10% homogenate) dilution of vCJD brain in blood. This sensitivity was 10 times better than the previous blinded panel results obtained with an earlier version of the assay and confirms Amorfix's internal testing program. In addition, the assay was able to detect with 100% accuracy spiked blood samples up to a dilution of 1:10,000 (1:1000 dilution of 10% homogenate) of vCJD spleen. Spleen has a lower amount of prions that are believed to be similar to prions in the blood of people infected with vCJD.

In addition, a test that uses larger volumes of blood has been developed and can detect a 1:20,000,000 (1:2,000,000 of a 10% homogenate) dilution of brain in blood. This test could be used to verify the initial positive reaction of the screening assay and confirm the results. The blood transfusion services worldwide require a very sensitive and specific assay for vCJD.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to

developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---